Herein, we aim to specifically evaluate the feasibility of BRCA1/2 testing by using an amplicon based Next Generation Sequencing (NGS) panel on a consecutive series of FFPE pancreatic tumor specimens, including FNAs, biopsies and surgical resections (tissue standard sections and macrosections). Here, BRCA1 is linked to pancreatic neoplasm.